NasdaqGM - Delayed Quote USD

Oculis Holding AG (OCSAW)

Compare

11.29

-0.21

(-1.80%)

At close: 3:59:58 PM EST

Oculis updates share capital for its existing at-the-market offering program

ZUG, Switzerland, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company, has issued registered ordinary shares of the Company, each with a nominal value of CHF 0.01, issued out of existing capital band (Kapitalband), for an aggregate of 2,500,000 ordinary shares of the Company (the "New Shares"), recorded as treasury shares. The number of registered shares issued by the Company as per its Articles of Associati

GlobeNewswire 4 minutes ago

OCS
+2.51%
OCSAW
-1.80%
Oculis Trial Shows Potential for Optical Neuroprotective Therapy

By Karen Roman Oculis Holding AG (Nasdaq: OCS) said Phase 2 of its neuroprotective candidate OCS-05 met key endpoints of safety and efficacy, highlighting its potential to treat acute optic neuritis. Oculis also said it received the Investigational New Drug application clearance from the FDA. “We are excited to further advance OCS-05’s development in acute […]

Exec Edge 24 days ago

OCS
+2.51%
OCSAW
-1.80%
Oculis Announces Positive OCS-05 Phase 2 ACUITY Trial in Acute Optic Neuritis, Met Primary Safety Endpoint and Key Secondary Efficacy Endpoints Opening Development Pathways as a Potential First-in-Class Neuroprotective Therapy

Oculis Announces Positive OCS-05 Phase 2 ACUITY Trial in Acute Optic Neuritis, Met Primary Safety Endpoint and Key Secondary Efficacy Endpoints Opening Development Pathways as a Potential First-in-Class Neuroprotective Therapy OCS-05 showed a favorable safety and tolerability profile compared to placeboAchieved statistically significant results on key secondary efficacy endpoints compared to placebo, including objective structural measures of retinal thickness and visual improvementIND clearance

GlobeNewswire 25 days ago

OCS
+2.51%
OCSAW
-1.80%
Oculis to Present at the Stifel 2024 Healthcare Conference

ZUG, Switzerland, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced that Oculis’ management will be present at the Stifel 2024 Healthcare Conference being held on November 18-19, 2024 at the Lotte New York Palace Hotel in New York, NY. Sylvia Cheung, Chief Financial Officer of Oculis, will participate in a fireside chat on November 18, 2024 at 3:35 pm ET. A live

GlobeNewswire 2 months ago

OCS
+2.51%
OCSAW
-1.80%
Oculis Holding Third Quarter 2024 Earnings: Misses Expectations

Oculis Holding ( NASDAQ:OCS ) Third Quarter 2024 Results Key Financial Results Net loss: CHF20.2m (loss widened by 16...

Simply Wall St. 2 months ago

OCS
+2.51%
OCSAW
-1.80%
Oculis Reports Q3 2024 Financial Results and Provides Company Updates

Significant advancement on product portfolio, including enrollment in the OCS-01 DIAMOND Phase 3 program in DME and OCS-05 Phase 2 ACUITY trial in acute optic neuritis (AON) with topline readout anticipated in December 2024Leadership team bolstered with extensive experience in key areas as the Company advances its late-stage pipeline and prepares for commercial phaseCash, cash equivalents and short-term investments of $125.0 million as of September 30, 2024, provides cash runway into 2H 2026 ZUG

GlobeNewswire 2 months ago

OCS
+2.51%
OCSAW
-1.80%
Oculis Holding AG's (NASDAQ:OCS) largest shareholders are individual investors with 56% ownership, institutions own 39%

Key Insights Oculis Holding's significant individual investors ownership suggests that the key decisions are influenced...

Simply Wall St. 3 months ago

OCS
+2.51%
OCSAW
-1.80%
Oculis Accelerates Enrollment in both DIAMOND Phase 3 Trials of OCS-01 in Diabetic Macular Edema and Expands its DIAMOND Program Committees

ZUG, Switzerland, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Phase 3 DIAMOND-1 and DIAMOND-2 trials enrollment of OCS-01 in diabetic macular edema (DME) accelerated with great momentumDIAMOND program committees expanded with globally renowned retina experts If approved, OCS-01 has the potential to transform the treatment paradigm as the first topical eye drop to treat DME Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care,

GlobeNewswire 3 months ago

OCS
+2.51%
OCSAW
-1.80%
Oculis’ DIAMOND Phase 3 Program in Diabetic Macular Edema to be Presented at Innovate Retina and Eyecelerator 2024

ZUG, Switzerland, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced that an update on the DIAMOND Phase 3 program with OCS-01, an OPTIREACH® formulation of high concentration dexamethasone eye drop, for diabetic macular edema (DME) will be presented by David Eichenbaum, M.D. at Innovate Retina. In addition, Riad Sherif, M.D., Oculis’ Chief Executive Officer, will

GlobeNewswire 3 months ago

OCS
+2.51%
OCSAW
-1.80%
Oculis Announces Appointment of Daniel S. Char as Chief Legal Officer

Mr. Char brings extensive experience in leading legal, compliance and corporate governance functions in successful biotech and medical device companiesThe appointment further expands Oculis’ leadership team as the company advances its late-stage pipeline and prepares for commercial phase ZUG, Switzerland, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced the appo

GlobeNewswire 3 months ago

OCS
+2.51%
OCSAW
-1.80%
Oculis and EURETINA Announce the Winner of the Inaugural Ramin Tadayoni Award

ZUG, Switzerland, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, in collaboration with EURETINA, today announced the winner of the Inaugural Ramin Tadayoni Award. The Ramin Tadayoni Award was established in memory of Oculis’ Chief Scientific Officer and a world-renowned retina specialist in order to pay a lasting tribute to Professor Tadayoni’s legacy, who passed away unexpe

GlobeNewswire 4 months ago

OCS
+2.51%
OCSAW
-1.80%
Oculis Holding (NASDAQ:OCS) Is In A Good Position To Deliver On Growth Plans

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Simply Wall St. 4 months ago

OCS
+2.51%
OCSAW
-1.80%
Oculis to Present at Upcoming September Investor Conferences

ZUG, Switzerland, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced that Oculis’ management will be attending and presenting at the following upcoming investor conferences: Wells Fargo Healthcare Conference 2024Event dates: September 4-6, 2024Location: Encore Boston Harbor, Boston, MA H.C. Wainwright 26th Annual Global Investment ConferenceEvent dates: September

GlobeNewswire 5 months ago

OCS
+2.51%
OCSAW
-1.80%
Oculis Reports Q2 2024 Financial Results and Provides Recent Company Update

Reported positive topline results for the Phase 2b RELIEF trial of OCS-02 (licaminlimab) paving the way for potentially the first precision medicine in Dry Eye Disease (DED)Phase 2 ACUITY trial of OCS-05 in acute optic neuritis (AON) is on track for topline readout in Q4 2024Pre-NDA meeting with U.S. Food and Drug Administration (FDA) completed in August for once daily OCS-01 for the treatment of post-operative inflammation and pain following ocular surgery; Providing a clear path forward for ND

GlobeNewswire 5 months ago

OCS
+2.51%
OCSAW
-1.80%
Oculis Reports Q2 Financial Results and Provides Recent Company Update

ZUG, Switzerland, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Reported positive topline results for the Phase 2b RELIEF trial of OCS-02 (licaminlimab) paving the way for potentially the first precision medicine in Dry Eye Disease (DED)Phase 2 ACUITY trial of OCS-05 in acute optic neuritis (AON) is on track for topline readout in Q4 2024Pre-NDA meeting with U.S. Food and Drug Administration (FDA) completed in August for once daily OCS-01 for the treatment of post-operative inflammation and pain following o

GlobeNewswire 5 months ago

OCS
+2.51%
OCSAW
-1.80%
Oculis Appoints Sharon Klier, M.D., M.S., M.P.H. as Chief Development Officer

ZUG, Switzerland, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced the appointment of Dr. Sharon Klier, an executive leader with extensive experience in clinical development across early and late-stage programs, regulatory submissions, and approvals, to the role of Chief Development Officer. In this key role, Dr. Klier will oversee and provide strategic leadersh

GlobeNewswire 5 months ago

OCS
+2.51%
OCSAW
-1.80%
Oculis to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

ZUG, Switzerland, July 30, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced that Oculis’ management will be participating at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference. Riad Sherif, M.D., Chief Executive Officer of Oculis, will participate in a panel discussion titled “Derisked Late-stage Candidates for Retinal Disorders” on August 15, 2024, at 11:00

GlobeNewswire 5 months ago

OCS
+2.51%
OCSAW
-1.80%
Oculis and EURETINA Announces the Ramin Tadayoni Award

ZUG, Switzerland, June 27, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, announces, in collaboration with EURETINA, the Ramin Tadayoni Award. In memory of the Company’s Chief Scientific Officer and a world-renowned retina specialist, EURETINA and Oculis have come together to pay a lasting tribute to Professor Tadayoni’s legacy. In this effort, EURETINA has

GlobeNewswire 7 months ago

OCS
+2.51%
OCSAW
-1.80%
Oculis Announces Positive Topline Results of Phase 2b RELIEF Trial with Licaminlimab, Designed to Transform the Treatment Paradigm of Dry Eye Disease with a Precision Medicine Strategy

Improvements in multiple sign efficacy endpoints were observed in full population and with predictive and more pronounced effects in the TNFR1 genetic biomarker population as identified in prior successful Phase 2 symptoms trialRapid treatment effect on corneal inflammation was observed in TNFR1 genetic biomarker patients as early as Day 15 and was statistically significant at final efficacy visit on Day 43Licaminlimab was well tolerated similar to vehicle Company plans to finalize Phase 3 devel

GlobeNewswire 7 months ago

OCS
+2.51%
OCSAW
-1.80%
Oculis Publishes Results of 2024 Annual General Meeting and Announces Appointments to its Board of Directors and Scientific Advisory Board

Shareholders approved all agenda items and proposals of the Board of DirectorsRobert K. Warner, M.B.A. and Arshad M. Khanani, M.D., M.A., FASRS elected as members of the Board of DirectorsBaruch D. Kuppermann, M.D., Ph.D. and Frank G. Holz, M.D., Ph.D. appointed as members of the Scientific Advisory BoardOculis established a CHF 50 million flexible loan facility with funds and accounts managed by BlackRock ZUG, Switzerland, May 30, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: O

GlobeNewswire 7 months ago

OCS
+2.51%
OCSAW
-1.80%
ALC

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Oculis Holding AG (OCSAW)

Oculis updates share capital for its existing at-the-market offering program

Oculis Trial Shows Potential for Optical Neuroprotective Therapy

Oculis Announces Positive OCS-05 Phase 2 ACUITY Trial in Acute Optic Neuritis, Met Primary Safety Endpoint and Key Secondary Efficacy Endpoints Opening Development Pathways as a Potential First-in-Class Neuroprotective Therapy

Oculis to Present at the Stifel 2024 Healthcare Conference

Oculis Holding Third Quarter 2024 Earnings: Misses Expectations

Oculis Reports Q3 2024 Financial Results and Provides Company Updates

Oculis Holding AG's (NASDAQ:OCS) largest shareholders are individual investors with 56% ownership, institutions own 39%

Oculis Accelerates Enrollment in both DIAMOND Phase 3 Trials of OCS-01 in Diabetic Macular Edema and Expands its DIAMOND Program Committees

Oculis’ DIAMOND Phase 3 Program in Diabetic Macular Edema to be Presented at Innovate Retina and Eyecelerator 2024

Oculis Announces Appointment of Daniel S. Char as Chief Legal Officer

Oculis and EURETINA Announce the Winner of the Inaugural Ramin Tadayoni Award

Oculis Holding (NASDAQ:OCS) Is In A Good Position To Deliver On Growth Plans

Oculis to Present at Upcoming September Investor Conferences

Oculis Reports Q2 2024 Financial Results and Provides Recent Company Update

Oculis Reports Q2 Financial Results and Provides Recent Company Update

Oculis Appoints Sharon Klier, M.D., M.S., M.P.H. as Chief Development Officer

Oculis to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

Oculis and EURETINA Announces the Ramin Tadayoni Award

Oculis Announces Positive Topline Results of Phase 2b RELIEF Trial with Licaminlimab, Designed to Transform the Treatment Paradigm of Dry Eye Disease with a Precision Medicine Strategy

Oculis Publishes Results of 2024 Annual General Meeting and Announces Appointments to its Board of Directors and Scientific Advisory Board